| Dr Emer Colalillo, MD | |
|
834 Eaton Ave, Bethlehem, PA 18018-1832 | |
| (484) 526-7474 | |
| Not Available |
| Full Name | Dr Emer Colalillo |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 9 Years |
| Location | 834 Eaton Ave, Bethlehem, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043600760 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD467524 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| St Luke's Hospital - Monroe Campus | Stroudsburg, PA | Hospital |
| St Luke's Hospital - Anderson Campus | Easton, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Luke's Physician Group Inc | 6709798333 | 1739 |
News Archive
Patients hospitalized with heart attacks tend to get faster and more comprehensive care if they arrive during daytime hours, according to a report in Circulation: Journal of the American Heart Association.
Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.
Research published by the University of Helsinki, Finland, indicates that cytostatic and radiation therapies administered before stem cell transplantation often damage children's permanent teeth.
The FDA has approved the addition of a secondary supplier of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.
› Verified 3 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
Patients hospitalized with heart attacks tend to get faster and more comprehensive care if they arrive during daytime hours, according to a report in Circulation: Journal of the American Heart Association.
Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.
Research published by the University of Helsinki, Finland, indicates that cytostatic and radiation therapies administered before stem cell transplantation often damage children's permanent teeth.
The FDA has approved the addition of a secondary supplier of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.
› Verified 3 days ago
| Entity Name | Star Community Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033686159 PECOS PAC ID: 7618215237 Enrollment ID: O20190206002009 |
News Archive
Patients hospitalized with heart attacks tend to get faster and more comprehensive care if they arrive during daytime hours, according to a report in Circulation: Journal of the American Heart Association.
Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.
Research published by the University of Helsinki, Finland, indicates that cytostatic and radiation therapies administered before stem cell transplantation often damage children's permanent teeth.
The FDA has approved the addition of a secondary supplier of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emer Colalillo, MD 801 Ostrum St, Bethlehem, PA 18015-1000 Ph: (484) 526-4000 | Dr Emer Colalillo, MD 834 Eaton Ave, Bethlehem, PA 18018-1832 Ph: (484) 526-7474 |
News Archive
Patients hospitalized with heart attacks tend to get faster and more comprehensive care if they arrive during daytime hours, according to a report in Circulation: Journal of the American Heart Association.
Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.
Research published by the University of Helsinki, Finland, indicates that cytostatic and radiation therapies administered before stem cell transplantation often damage children's permanent teeth.
The FDA has approved the addition of a secondary supplier of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.
› Verified 3 days ago
Carolyn Botros, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1770 Bathgate Rd Ste 401, Bethlehem, PA 18017 Phone: 484-884-8840 Fax: 484-884-8827 | |
Sarah Jane Cathryn Muder, DO Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 801 Ostrum St, Bethlehem, PA 18015 Phone: 484-503-8217 | |
Dr. Anita Sargent, M.D., PH.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 325 W Broad St, 3rd Floor, Bethlehem, PA 18018 Phone: 424-626-9250 Fax: 484-626-9255 | |
Dr. Kathleen Eleanor Ackert, DO Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 801 Ostrum St, Bethlehem, PA 18015 Phone: 484-526-4670 | |
Dr. John Roizin, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 31 S Commerce Way, Bethlehem, PA 18017 Phone: 484-821-0821 Fax: 484-821-0826 | |
Dr. Melat Worku Tiruneh, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 801 Ostrum St, Bethlehem, PA 18015 Phone: 484-526-4670 Fax: 833-828-1814 |